InflaRx Cuts 30% of Workforce, Deprioritizes COVID-19 Therapy to Focus on Immunology Pipeline
核心洞察
InflaRx (搜索) announced a 30% workforce reduction and strategic pivot away from COVID-19 (搜索) antibody therapy Gohibic following its failure in late-stage trials for pyoderma gangrenosum (搜索).
The German biotech will incur approximately $7 million in one-time restructuring costs, primarily non-cash charges from writing off Gohibic inventory.
The company is redirecting resources toward izicopan (搜索), an investigational C5a pathway (搜索) inhibitor in mid-stage development for chronic spontaneous urticaria (搜索) and hidradenitis suppurativa (搜索).
German biotech InflaRx (搜索) has announced a significant restructuring initiative involving a 30% workforce reduction and strategic deprioritization of its COVID-19 (搜索) antibody therapy Gohibic. The company is pivoting resources toward its immunology pipeline, particularly its investigational C5a pathway (搜索) inhibitor izicopan (搜索), as it seeks to streamline operations and extend its financial runway.
Strategic Shift Away from COVID-19 Therapy
The decision to deprioritize Gohibic comes after the therapy's disappointing performance in clinical trials beyond its original COVID-19 (搜索) indication. While Gohibic received FDA emergency use authorization in 2023 for treating COVID-19 in hospitalized patients, InflaRx (搜索) pulled the plug on a late-stage study in pyoderma gangrenosum (搜索), a rare skin disease, in March last year after the asset failed to meet expectations.
The restructuring will result in approximately $7 million in one-time costs for InflaRx (搜索), with the majority consisting of non-cash charges related to writing off Gohibic inventory. Despite these immediate costs, the company expects the operational changes to extend its financial runway into mid-2027.
Focus on Izicopan Development
With the workforce reduction and resource reallocation, InflaRx (搜索) is positioning itself to advance izicopan (搜索), an investigational inhibitor of the C5a pathway (搜索). The compound is currently in mid-stage development for chronic spontaneous urticaria (搜索) (CSU) and hidradenitis suppurativa (搜索) (HS), with Phase I studies underway for other immune skin conditions.
The company is actively engaged in discussions with the FDA regarding its Phase IIb trial design for izicopan (搜索) in HS. These regulatory conversations aim to align on relevant endpoints that would "meaningfully differentiate izicopan from existing therapies" available for HS treatment. InflaRx (搜索) is also working to address "variability inherent in some HS trial outcomes" as part of these discussions.
Regulatory Timeline and Data Presentation
While InflaRx (搜索) stated it is "moving as quickly as is feasible" in its regulatory discussions, the company has not provided a definitive timeline for completing these FDA conversations. The biotech plans to present Phase IIa data for both HS and CSU indications at medical conferences later this year.
The strategic pivot represents InflaRx (搜索)'s response to previous challenges, as the company had indicated in March that it was "considering additional cost savings and redirection of resources" following Gohibic's trial failure. The current restructuring initiative fulfills that earlier strategic warning while positioning the company to focus on its most promising immunology assets.